Basit öğe kaydını göster

dc.contributor.authorSırma Ekmekci, Sema
dc.contributor.authorDeniz, Günnur
dc.contributor.authorAbacı, Neslihan
dc.contributor.authorÇınar, Suzan
dc.contributor.authorSalman, Burcu
dc.date.accessioned2021-12-10T11:04:58Z
dc.date.available2021-12-10T11:04:58Z
dc.date.issued2021
dc.identifier.citationSalman B., Sırma Ekmekci S., Çınar S., Deniz G., Abacı N., "DHRS2 is a potential marker of breast cancer metastasis", Gene Reports, cilt.25, sa.1, ss.1-5, 2021
dc.identifier.othervv_1032021
dc.identifier.otherav_67115ccf-cb65-45df-b157-613f9e9ab6ad
dc.identifier.urihttp://hdl.handle.net/20.500.12627/171188
dc.identifier.urihttps://doi.org/10.1016/j.genrep.2021.101302
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/67115ccf-cb65-45df-b157-613f9e9ab6ad/file
dc.description.abstractBackgroundAlthough breast cancer treatment success has increased, biomarkers are still important. The dehydrogenase/reductase DHRS2 has a role in the metabolic and survival activities of cells. DHRS2 directly binds MDM2 and inhibits the cellular processes of p53. Our study aimed to examine cellular response to inhibit DHRS2 gene expression in the breast cancer cell line MCF7.Methods and resultsThe RNAi suppressed DHRS2 expression has been investigated in the breast carcinoma cell line MCF7 and, different study groups were formed to observe the impact. Afterward, an apoptotic marker was applied to the groups for measuring the amount of apoptotic and necrotic cells by flow cytometer. Cells were stained withtrypan blueforcell viability, and we used anMTT assayforcellular proliferationmeasurement. Finally, migration experiments were performed using the wound healing model, and their gap width was calculated with the ImageJ program. Comparing to the non-transfected cells (NTC), the apoptotic cell number of non-targeting (NT) and DHRS2 siRNA (si-DHRS2) transfected groups had less quantity. While there was no critical difference in proliferation and viability, DHRS2 deficient cells gave the lowest closure rate than control groups in migration tests. The gene silencing rates of all groups were controlled by quantitative PCR.ConclusionsThe migration assay results of DHRS2 inhibition, the gene popularity is increasing day by day in the literature, will be pioneers for metastasis studies. It is also usual that cell apoptosis and proliferation, which have many regulatory mechanisms, are not critically affected by the absence of DHRS2.
dc.language.isoeng
dc.subjectGeneral Health Professions
dc.subjectKlinik Tıp (MED)
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectHealth Sciences
dc.subjectTIP, GENEL & İÇECEK
dc.subjectBİYOLOJİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectTıbbi Biyoloji
dc.subjectDiğer
dc.subjectFamily Practice
dc.subjectFundamentals and Skills
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectBiyoloji ve Biyokimya
dc.titleDHRS2 is a potential marker of breast cancer metastasis
dc.typeMakale
dc.relation.journalGene Reports
dc.contributor.departmentİstanbul Üniversitesi , Aziz Sancar Deneysel Tıp Araştırma Enstitüsü , Genetik Ana Bilim Dalı
dc.identifier.volume25
dc.identifier.issue1
dc.identifier.startpage1
dc.identifier.endpage5
dc.contributor.firstauthorID2717645


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster